Takeda Oncology is hitting the ice with Boston Defenseman Charlie McAvoy in support of the lung cancer community with the #PowerPlayForPatients initiative.
Lung cancer is the second most common cancer in both men and women. Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of the estimated 222,500 new cases of lung cancer diagnosed each year in the United States. NSCLC can manifest in several different genetics variations. Between 2% and 8% of NSCLC cases are anaplastic lymphoma kinase (ALK) positive.
This hockey season, every time Boston goes on a power play, Takeda Oncology makes a donation to the Lung Cancer Research Foundation to support vital lung cancer research and patient programs. If the B's on the ice score a power play goal, the donation will be doubled.
With Gold and Black on our side, we're sure to shutout lung cancer. Join us to cheer on the B’s on the ice to help raise funds for vital lung cancer research. Learn more at www.takedaoncology.com and follow #PowerPlayForPatients.
This is a paid advertisement.